Novel &amp; effective management of capecitabine induced Hand Foot Syndrome

Pendharkar, Dinesh; Goyal, H.

doi:10.1200/jco.2004.22.90140.8105

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current strategies may include emollients, topical corticosteroids, keratolytics, and sildenafil. [54][55][56] In clinical practice, respondents to the DCCG survey reported that they recommend emollients, loose clothing and shoes, and refer their patients to the oncology nurse for guidance on prevention and treatment of HFS. 10 In Table 2 we provide recommendations for preventive and symptomatic treatment of HFS based on available evidence and expert opinion.…”

Section: Symptom Ameliorationmentioning

confidence: 99%

Management of cytotoxic chemotherapy-induced hand-foot syndrome

Kwakman¹,

Elshot²,

Punt³

et al. 2020

Oncol Rev

View full text Add to dashboard Cite

Improvements in systemic cancer treatments have resulted in more patients surviving for prolonged periods of time on treatment. This has made treatment-related toxicity and quality of life concerns increasingly relevant. Hand-foot syndrome (HFS) is a common skin reaction to systemic therapy that should be anticipated with chemotherapeutic treatments such as pegylated liposomal doxorubicin, docetaxel, and fluoropyrimidines. In this review we discuss current knowledge of the diagnosis, incidence, pathogenesis, and management of hand-foot syndrome (HFS). Although HFS is not life threatening, it can cause significant discomfort and impairment of function, especially in elderly patients, and may seriously impact quality of life. The incidence of HFS is dependent on the chemotherapeutic drug used, the treatment schedule, and the median duration of treatment. Effective measures for prevention and treatment of HFS include systemic and topical treatments, dose reductions, and switching to other drugs in the same class that are associated with lower rates of HFS. These approaches allow patients to continue cancer treatment while reducing negative impacts on quality of life. Awareness and early recognition are important to ensure timely treatment and avoidance of dose reductions or treatment discontinuation. We provide useful recommendations to guide the management of HFS in clinical practice.

show abstract

Section: Symptom Ameliorationmentioning

confidence: 99%

Management of cytotoxic chemotherapy-induced hand-foot syndrome

Kwakman¹,

Elshot²,

Punt³

et al. 2020

Oncol Rev

View full text Add to dashboard Cite

show abstract

“…Leicher e colaboradores (2017) relataram 44,2% de taxa de eventos gastrointestinais em pacientes em monoterapia com capecitabina para tratamento de câncer colorretal metastático. 31 38,39 Os EA leves não provocaram mudanças no tratamento com capecitabina, ou seja, estes foram gerenciados com medidas de suporte sem necessidade de modificar o tratamento.…”

Section: Discussionunclassified

Avaliação dos efeitos adversos em pacientes em uso de capecitabina: um estudo randomizado

Dos Santos,

De Oliveira,

Marinho

et al. 2023

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

Introdução: A capecitabina é um medicamento oral utilizado na terapia anticâncer e pode causar efeitos adversos (EA) com implicações clínicas no tratamento e na qualidade de vida dos pacientes. Farmacêuticos oncológicos podem desempenhar importante papel no gerenciamento dos EA. No entanto, são escassos estudos que avaliam o impacto clínico desses. Este estudo tem como objetivo identificar as consequências clínicas dos EA à capecitabina no tratamento dos pacientes com câncer colorretal, câncer gástrico e câncer anal em um hospital de referência em oncologia na cidade do Rio de Janeiro, Brasil. Métodos: Estudo longitudinal, prospectivo e randomizado com pacientes em uso de capecitabina entre abril e outubro de 2022. Os EA foram classificados quanto à gravidade. As consequências clínicas dos EA foram avaliadas por meio da suspensão temporária ou definitiva do tratamento e/ou redução da dose de capecitabina. A análise estatística foi conduzida pelos Testes de Fisher, Qui-quadrado e Shapiro - Wilk. Resultados: Foram incluídos no estudo 25 pacientes, com idade média de 59,6 anos. Os EA mais frequentes foram diarreia (60,0%), náusea (48,0%) e vômito (32,0%). A maioria dos EA (87,9%) ocorreu em grau leve e durante o primeiro ou segundo ciclo de quimioterapia (52,9%). Conclusões: O estudo evidenciou que os EA à capecitabina causam consequências clínicas ao tratamento do paciente. A menor gravidade de síndrome mão-pé sugere a eficácia da medida preventiva de distribuição de hidratante e educação do paciente, além de tornar essencial o Acompanhamento Farmacoterapêutico na identificação dos efeitos adversos e implementação de medidas de manejo com melhorias na qualidade do tratamento dos pacientes em uso de capecitabina.

show abstract

“…Capecitabine is used as an adjuvant treatment in colorectal cancer; as the first-line treatment in metastatic colorectal, gastric, pancreatic, and head and neck cancers; and as monotherapy or in combination with docetaxel in metastatic breast cancer (1). Although capecitabine is well tolerated by patients, hand-foot syndrome (HFS) is one of the common adverse events, which causes a significant degree of morbidity (2,3). HFS was first described by Zuehlke in 1974 as an erythematous/malignant rash on the hands and toes of patients who received mitotane (4).…”

Section: Introductionmentioning

confidence: 99%

Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports

ARAS¹,

YÜCEL²,

EKİNCİOĞLU³

et al. 2019

Clinical and Experimental Health Sciences

View full text Add to dashboard Cite

Objective: Capecitabine, a prodrug of 5-fluorouracil, is currently used in the treatment of metastatic colorectal and breast cancers. The aim of this study was to review the pharmacological mechanisms, treatment strategies, and documented case reports of capecitabine-induced hand-foot syndrome (HFS). Methods: All case reports documented in the PubMed, Web of Science, and Scopus databases up to February 2018 were searched and reviewed using the keywords capecitabine, hand-foot syndrome, and case report. Results: The database search identified 373 articles in the literature; of these, 88 articles (having 111 case reports) in the English or Turkish language having a full-text access were included in the study. The median duration of capecitabine-induced HFS was 28 (range, 7-140) days, and the daily dose of capecitabine ranged between 850 and 5000 mg/m2 in cases wherein capecitabine was applied as monotherapy(n=19). A dose reduction or treatment discontinuation, systemic or topical treatment alone or in combination, and the use of henna, vitamin E, or pyridoxine were preferred options in the treatment of HFS. Conclusion: Health care providers and patients should be aware of developing capecitabine-induced HFS and its risk factors. Early recognition and treatment initiation for HFS are important to maintain effective chemotherapy in patients with cancer.

show abstract

Novel & effective management of capecitabine induced Hand Foot Syndrome

Cited by 9 publications

References 0 publications

Management of cytotoxic chemotherapy-induced hand-foot syndrome

Management of cytotoxic chemotherapy-induced hand-foot syndrome

Avaliação dos efeitos adversos em pacientes em uso de capecitabina: um estudo randomizado

Capecitabine Induced Hand-Foot Syndrome: A Systematic Review of Case Reports

Contact Info

Product

Resources

About